CCXI · Insider Trading
Churchill Capital Corp XI Class A Ordinary Shares
Every open-market purchase and sale reported by CCXI officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2022-10-24 | David E. Wheadon | Director | D | −22,274 deriv. | — |
| 2022-10-24 | Jennifer Lyn Herron | Director | D | −17,237 | — |
| 2022-10-24 | Susan M Kanaya | See Remarks | D | −224,034 | — |
| 2022-10-24 | Thomas J. Schall | President and CEO | D | −2,393,352 | — |
| 2022-10-24 | Joseph M Feczko | Director | D | −148,127 | — |
| 2022-10-24 | Rita Jain | EVP, Chief Medical Officer | D | −35,863 | — |
| 2022-10-24 | Geoffrey M. Parker | Director | D | −134,073 | — |
| 2022-10-24 | Tausif Butt | EVP, Chief Operating Officer | D | −10,870 | — |
| 2022-10-24 | Markus J. Cappel | Chief Bus. Officer & Treasurer | D | −87,658 | — |
| 2022-10-24 | Thomas A. Edwards | Director | D | −143,306 | — |
| 2022-10-24 | James L Tyree | Director | D | −9,138 | — |
| 2022-08-18 | Susan M Kanaya | EVP, CFO and Sec. | MIXED | — | −$797.70K |
| 2022-08-08 | Markus J. Cappel | Chief Bus. Officer & Treasurer | Sell | −7,564 | −$379.86K |
| 2022-08-08 | James L Tyree | Director | Sell | −10,000 | −$502.20K |
| 2022-08-08 | Thomas J. Schall | President and CEO | MIXED | — | −$4.68M |
| 2022-08-08 | Susan M Kanaya | EVP, CFO and Sec. | MIXED | — | −$2.02M |
| 2022-06-30 | Jennifer Lyn Herron | Director | A | +17,237 | — |
| 2022-06-13 | James L Tyree | Director | Sell | −3,863 | −$99.13K |
| 2022-06-08 | Yi Ching Yau | SVP, Finance & Acctg Officer | A | +65,000 deriv. | — |
| 2022-05-31 | Thomas A. Edwards | Director | A | +15,723 | — |
| 2022-05-31 | David E. Wheadon | Director | A | +22,274 deriv. | — |
| 2022-05-31 | James L Tyree | Director | A | +24,065 deriv. | — |
| 2022-05-31 | Joseph M Feczko | Director | A | +24,065 deriv. | — |
| 2022-05-31 | Geoffrey M. Parker | Director | A | +24,065 deriv. | — |
| 2022-05-24 | James L Tyree | Director | M | +7,726 | — |
| 2022-05-24 | Henry A McKinnell | Director | M | +7,726 | — |
| 2022-05-24 | Geoffrey M. Parker | Director | M | +7,726 | — |
| 2022-05-24 | Rita Jain | EVP, Chief Medical Officer | M | +7,726 | — |
| 2022-05-03 | Geoffrey M. Parker | Director | M | +12,500 | +$180.25K |
| 2022-03-29 | Rita Jain | EVP, Chief Medical Officer | M | +5,251 | — |
| 2022-02-25 | Thomas J. Schall | President and CEO | A | +345,300 deriv. | — |
| 2022-02-24 | Markus J. Cappel | Chief Bus. Officer & Treasurer | A | +92,100 deriv. | — |
| 2022-02-24 | Susan M Kanaya | EVP, CFO and Sec. | A | +134,900 deriv. | — |
| 2022-02-24 | Tausif Butt | EVP, Chief Operating Officer | A | +93,600 deriv. | — |
| 2022-02-24 | Rita Jain | EVP, Chief Medical Officer | A | +26,300 deriv. | — |
| 2022-01-25 | Joseph M Feczko | Director | M | +37,500 | +$577.75K |
| 2022-01-04 | Markus J. Cappel | Chief Bus. Officer & Treasurer | MIXED | +9,396 | −$420.10K |
| 2022-01-04 | Thomas J. Schall | President and CEO | MIXED | +38,536 | −$1.66M |
| 2022-01-04 | Susan M Kanaya | EVP, CFO and Sec. | MIXED | +13,952 | −$613.40K |
| 2021-12-21 | James L Tyree | Director | MIXED | — | −$817.41K |
| 2021-12-03 | Thomas J. Schall | President and CEO | M | +45,936 | +$499.99K |
| 2021-10-13 | Vifor Pharma Ltd. | 10%+ Owner | Sell | −12,000,000 | −$473.16M |
| 2021-10-07 | Rita Jain | EVP, Chief Medical Officer | A | +45,000 deriv. | — |
| 2021-06-16 | Tausif Butt | EVP, Chief Operating Officer | A | +75,000 deriv. | — |
| 2021-05-24 | Joseph M Feczko | Director | A | +7,726 | — |
| 2021-05-24 | Thomas A. Edwards | Director | A | +7,726 | — |
| 2021-05-24 | Geoffrey M. Parker | Director | MIXED | +660 | — |
| 2021-05-24 | James L Tyree | Director | MIXED | +2,206 | −$23.96K |
| 2021-05-24 | Henry A McKinnell | Director | A | +12,230 deriv. | — |
| 2021-05-24 | Rita Jain | Director | M | +4,660 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the CCXI quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.